IDEXX Laboratories, Inc.
NASDAQ•IDXX
CEO: Mr. Jonathan J. Mazelsky
セクター: Healthcare
業種: Medical - Diagnostics & Research
上場日: 1991-06-21
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
連絡先情報
時価総額
$49.42B
PER (TTM)
46.8
20.4
配当利回り
--
52週高値
$769.98
52週安値
$356.14
52週レンジ
順位17Top 4.2%
6.4
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
強い • 6.4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$1.09B+14.28%
直近4四半期の推移
EPS
$3.10+17.87%
直近4四半期の推移
フリーCF
$322.59M+46.49%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Growth Strong Total revenue reached $4.304B, up 10.4% compared to prior year; organic growth was 9.6%.
Operating Profit Surges 20.5% Income from operations grew 20.5% to $1.360B, driven by gross profit margin expansion and productivity.
CAG Recurring Revenue Up CAG recurring revenue increased 8.9% to $3.407B, supported by higher volumes and realized prices.
Cash Flow From Operations Cash provided by operating activities increased $252.8M to $1.182B for the year ended December 31, 2025.
リスク要因
Intense Industry Competition Failure to execute strategy in highly competitive environment negatively impacts future growth and profitability outlook.
Supplier Dependence Risks Reliance on sole/single-source suppliers risks supply chain disruption, increased product costs, and potential customer loss.
Macroeconomic Vulnerability Demand sensitive to slow economic growth, inflation, and cautious consumer spending affecting patient visits and capital purchases.
LPD Segment Income Decline Livestock, Poultry, Dairy segment income dropped 51.3% to $3.229M due to higher product costs.
見通し
AI Integration Strategy Focus Continued investment in AI integration across products and internal operations to drive efficiency and customer value.
CAG Growth Drivers Identified Success depends on increasing utilization of consumables and successful placement of new IDEXX inVue Dx Analyzer.
Managing Global Currency Risk Anticipate favorable impacts from foreign currency hedging activity, though actual results depend on exchange rates.
Projected Capital Expenditures Projected capital expenditures for 2026 estimated at approximately $180.0M for growth and software development.
同業比較
売上高 (TTM)
$325.78B
$244.49B
$30.01B
粗利益率 (最新四半期)
89.3%
78.3%
75.6%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| COR | $69.89B | 42.9 | 101.4% | 10.1% |
| BDX | $61.57B | 27.6 | 6.9% | 35.6% |
| TAK | $56.11B | 78.8 | 1.6% | 31.5% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.0%
緩やかな成長
4四半期純利益CAGR
0.8%
収益性の緩やかな改善
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年4月29日
EPS:-
|売上高:-
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし